Dr Reddy’s Debuts US Vimovo Rival At Risk
Lupin Has Authorized Generic As Nuvo Cites Patents To 2022
Dr Reddy’s has announced the launch of the first US generic version of Vimovo delayed-release tablets. However, Nuvo has warned that the at-risk launch infringes patents protecting the arthritis pain treatment until May 2022.
You may also be interested in...
Dr Reddy’s Laboratories has once again prevailed over Horizon Pharma and Nuvo in litigation over patents shielding the originators’ Vimovo, with the US Court of Appeals for the Federal Circuit affirming a lower court's invalidity ruling.
With Erez Israeli set to step up from COO to CEO, Dr Reddy’s is looking to leverage its lack of debt and strong cash flow in the mergers and acquisitions arena.
Three generics players in the US have helped to clear the path for generic rivals to the Vimovo analgesic by winning an appeals verdict of written descriptions for two patents.